SEPTOCAINE (articaine hydrochloride; epinephrine bitartrate) by Pfizer is anesthetic. First approved in 2006.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
SEPTOCAINE is a local anesthetic injectable combining articaine hydrochloride with epinephrine bitartrate, approved in 2006 for infiltration anesthesia. It blocks nerve impulse generation and conduction while the epinephrine component acts as a vasoconstrictor to prolong anesthetic effect by slowing systemic absorption. Used primarily in dental and oral surgical procedures to provide local pain relief.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and transition focus toward market defense or pipeline support.
anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
SEPTOCAINE offers limited career growth opportunity with zero currently linked positions, reflecting its mature LOE-approaching status. Roles on this product focus on defending market share and managing transition to generic competition rather than launch or expansion activities.
Worked on SEPTOCAINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.